-
1
-
-
0141615827
-
Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II
-
Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003; 108: 1655-61.
-
(2003)
Circulation
, vol.108
, pp. 1655-1661
-
-
Luscher, T.F.1
Creager, M.A.2
Beckman, J.A.3
Cosentino, F.4
-
2
-
-
0037092995
-
Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management
-
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
-
(2002)
JAMA
, vol.287
, pp. 2570-2581
-
-
Beckman, J.A.1
Creager, M.A.2
Libby, P.3
-
3
-
-
0032560807
-
Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
-
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
-
(1998)
N Engl J Med
, vol.339
, pp. 229-234
-
-
Haffner, S.M.1
Lehto, S.2
Ronnemaa, T.3
Pyorala, K.4
Laakso, M.5
-
4
-
-
0031670506
-
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation
-
Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-9.
-
(1998)
J Am Coll Cardiol
, vol.32
, pp. 584-589
-
-
Abizaid, A.1
Kornowski, R.2
Mintz, G.S.3
-
5
-
-
79551499429
-
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction
-
Thune JJ, Signorovitch JE, Kober L, et al. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail 2011; 13: 148-53.
-
(2011)
Eur J Heart Fail
, vol.13
, pp. 148-153
-
-
Thune, J.J.1
Signorovitch, J.E.2
Kober, L.3
-
6
-
-
0141615827
-
Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I
-
Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-32.
-
(2003)
Circulation
, vol.108
, pp. 1527-1532
-
-
Creager, M.A.1
Luscher, T.F.2
Cosentino, F.3
Beckman, J.A.4
-
7
-
-
2042504400
-
Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control
-
Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113: 101-13.
-
(2004)
Thromb Res
, vol.113
, pp. 101-113
-
-
Watala, C.1
Golanski, J.2
Pluta, J.3
-
8
-
-
23644433510
-
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
-
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-5.
-
(2005)
Diabetes
, vol.54
, pp. 2430-2435
-
-
Angiolillo, D.J.1
Fernandez-Ortiz, A.2
Bernardo, E.3
-
10
-
-
77957113521
-
Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus
-
Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010; 126: e318-22.
-
(2010)
Thromb Res
, vol.126
-
-
Mortensen, S.B.1
Larsen, S.B.2
Grove, E.L.3
Kristensen, S.D.4
Hvas, A.M.5
-
11
-
-
15044348667
-
Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin
-
Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005;83:148-58.
-
(2005)
J Mol Med
, vol.83
, pp. 148-158
-
-
Watala, C.1
Pluta, J.2
Golanski, J.3
-
12
-
-
33846656039
-
Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation
-
Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-4.
-
(2007)
Diabetes Care
, vol.30
, pp. 372-374
-
-
Geisler, T.1
Anders, N.2
Paterok, M.3
-
13
-
-
55949127696
-
The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
-
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
-
(2008)
BMJ
, vol.337
-
-
Belch, J.1
McCuish, A.2
Campbell, I.3
-
14
-
-
56149113603
-
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial
-
Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41.
-
(2008)
JAMA
, vol.300
, pp. 2134-2141
-
-
Ogawa, H.1
Nakayama, M.2
Morimoto, T.3
-
15
-
-
84881264418
-
Aspirin for primary prevention of cardiovascular events in people with diabetes: Metaanalysis of randomised controlled trials
-
De BG, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: metaanalysis of randomised controlled trials. BMJ 2009; 339: b4531.
-
(2009)
BMJ
, vol.339
-
-
De, B.G.1
Sacco, M.2
Strippoli, G.F.3
-
16
-
-
34447503098
-
Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis
-
Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-9.
-
(2007)
Arch Intern Med
, vol.167
, pp. 1593-1599
-
-
Snoep, J.D.1
Hovens, M.M.2
Eikenboom, J.C.3
van der Bom, J.G.4
Huisman, M.V.5
-
17
-
-
34447576539
-
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
-
Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-31.
-
(2007)
Am Heart J
, vol.154
, pp. 221-231
-
-
Snoep, J.D.1
Hovens, M.M.2
Eikenboom, J.C.3
-
18
-
-
38949119325
-
Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis
-
Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8.
-
(2008)
BMJ
, vol.336
, pp. 195-198
-
-
Krasopoulos, G.1
Brister, S.J.2
Beattie, W.S.3
Buchanan, M.R.4
-
19
-
-
66949181207
-
Update on oral antiplatelet therapy: Principles, problems and promises
-
Grove EL, Kristensen SD. Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiol 2009; 5: 247-58.
-
(2009)
Future Cardiol
, vol.5
, pp. 247-258
-
-
Grove, E.L.1
Kristensen, S.D.2
-
20
-
-
0030795973
-
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
-
Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 171-9.
-
(1997)
J Am Coll Cardiol
, vol.30
, pp. 171-179
-
-
Mak, K.H.1
Moliterno, D.J.2
Granger, C.B.3
-
21
-
-
1242339648
-
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes
-
Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004; 25: 190-8.
-
(2004)
Eur Heart J
, vol.25
, pp. 190-198
-
-
Roffi, M.1
Topol, E.J.2
-
22
-
-
19944384222
-
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
-
Stuckey TD, Stone GW, Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 2005; 95: 1-7.
-
(2005)
Am J Cardiol
, vol.95
, pp. 1-7
-
-
Stuckey, T.D.1
Stone, G.W.2
Cox, D.A.3
-
23
-
-
79251478398
-
Contribution of platelets to tumour metastasis
-
Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-34.
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 123-134
-
-
Gay, L.J.1
Felding-Habermann, B.2
-
25
-
-
66049107647
-
Platelet receptors and signaling in the dynamics of thrombus formation
-
Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009; 94: 700-11.
-
(2009)
Haematologica
, vol.94
, pp. 700-711
-
-
Rivera, J.1
Lozano, M.L.2
Navarro-Nunez, L.3
Vicente, V.4
-
26
-
-
77950635286
-
Basic principles of platelet biology and clinical implications
-
Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597-607.
-
(2010)
Circ J
, vol.74
, pp. 597-607
-
-
Angiolillo, D.J.1
Ueno, M.2
Goto, S.3
-
27
-
-
0037180771
-
Inflammation in atherosclerosis
-
Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
-
(2002)
Nature
, vol.420
, pp. 868-874
-
-
Libby, P.1
-
28
-
-
0027397638
-
Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions
-
Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med 1993; 328: 628-35.
-
(1993)
N Engl J Med
, vol.328
, pp. 628-635
-
-
Ware, J.A.1
Heistad, D.D.2
-
29
-
-
2542580838
-
The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction
-
Grove EL, Orntoft TF, Lassen JF, Jensen HK, Kristensen SD. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. J Intern Med 2004; 255: 637-44.
-
(2004)
J Intern Med
, vol.255
, pp. 637-644
-
-
Grove, E.L.1
Orntoft, T.F.2
Lassen, J.F.3
Jensen, H.K.4
Kristensen, S.D.5
-
30
-
-
42549168144
-
Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development
-
Kleiman NS, Freedman JE, Tracy PB, et al. Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. Platelets 2008; 19: 239-51.
-
(2008)
Platelets
, vol.19
, pp. 239-251
-
-
Kleiman, N.S.1
Freedman, J.E.2
Tracy, P.B.3
-
31
-
-
0036634743
-
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes
-
Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-34.
-
(2002)
Diabetes Care
, vol.25
, pp. 1129-1134
-
-
Hu, F.B.1
Stampfer, M.J.2
Haffner, S.M.3
-
32
-
-
0032560807
-
Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
-
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
-
(1998)
N Engl J Med
, vol.339
, pp. 229-234
-
-
Haffner, S.M.1
Lehto, S.2
Ronnemaa, T.3
Pyorala, K.4
Laakso, M.5
-
33
-
-
0035093810
-
Diabetes mellitus: A hypercoagulable state
-
Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
-
(2001)
J Diabetes Complications
, vol.15
, pp. 44-54
-
-
Carr, M.E.1
-
34
-
-
16844362676
-
Inflammatory, atherothrombotic aspects of type 2 diabetes
-
Grant PJ. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin 2005;21 (Suppl 1): S5-12.
-
(2005)
Curr Med Res Opin
, vol.21
, Issue.SUPPL. 1
-
-
Grant, P.J.1
-
35
-
-
34447633353
-
Diabetes mellitus as a prothrombotic condition
-
Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-72.
-
(2007)
J Intern Med
, vol.262
, pp. 157-172
-
-
Grant, P.J.1
-
36
-
-
34948907941
-
Sweet and sticky: Diabetic platelets, enhanced reactivity, and cardiovascular risk
-
Simon DI, Schmaier AH. Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. J Am Coll Cardiol 2007; 50: 1548-50.
-
(2007)
J Am Coll Cardiol
, vol.50
, pp. 1548-1550
-
-
Simon, D.I.1
Schmaier, A.H.2
-
37
-
-
79952168736
-
Diabetes and antiplatelet therapy in acute coronary syndrome
-
Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011; 123: 798-813.
-
(2011)
Circulation
, vol.123
, pp. 798-813
-
-
Ferreiro, J.L.1
Angiolillo, D.J.2
-
38
-
-
49649090453
-
Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome
-
Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 2008; 31: 1590-5.
-
(2008)
Diabetes Care
, vol.31
, pp. 1590-1595
-
-
Undas, A.1
Wiek, I.2
Stepien, E.3
Zmudka, K.4
Tracz, W.5
-
39
-
-
0035077478
-
Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus
-
Yngen M, Ostenson CG, Li N, Hjemdahl P, Wallen NH. Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus. Blood Coagul Fibrinolysis 2001; 12: 109-16.
-
(2001)
Blood Coagul Fibrinolysis
, vol.12
, pp. 109-116
-
-
Yngen, M.1
Ostenson, C.G.2
Li, N.3
Hjemdahl, P.4
Wallen, N.H.5
-
40
-
-
79955155110
-
Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo
-
Vivas D, Garcia-Rubira JC, Bernardo E, et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo"). Heart 2011; 97: 803-9.
-
(2011)
Heart
, vol.97
, pp. 803-809
-
-
Vivas, D.1
Garcia-Rubira, J.C.2
Bernardo, E.3
-
41
-
-
77950658721
-
Influence of glycaemic control on platelet bound CD40-CD40L system, Pselectin and soluble CD40 ligand in Type 2 diabetes
-
Neubauer H, Setiadi P, Gunesdogan B, et al. Influence of glycaemic control on platelet bound CD40-CD40L system, Pselectin and soluble CD40 ligand in Type 2 diabetes. Diabet Med 2010; 27: 384-90.
-
(2010)
Diabet Med
, vol.27
, pp. 384-390
-
-
Neubauer, H.1
Setiadi, P.2
Gunesdogan, B.3
-
42
-
-
1642565073
-
Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes
-
Eibl N, Krugluger W, Streit G, et al. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004; 34: 205-9.
-
(2004)
Eur J Clin Invest
, vol.34
, pp. 205-209
-
-
Eibl, N.1
Krugluger, W.2
Streit, G.3
-
43
-
-
0025214340
-
Evidence for abnormal platelet glycoprotein expression in diabetes mellitus
-
Tschoepe D, Roesen P, Kaufmann L, et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990; 20: 166-70.
-
(1990)
Eur J Clin Invest
, vol.20
, pp. 166-170
-
-
Tschoepe, D.1
Roesen, P.2
Kaufmann, L.3
-
44
-
-
0035008904
-
Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus
-
Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001; 280: H1480-9.
-
(2001)
Am J Physiol Heart Circ Physiol
, vol.280
-
-
Li, Y.1
Woo, V.2
Bose, R.3
-
45
-
-
82255194187
-
Role of platelet plasma membrane Ca-ATPase in health and disease
-
Dean WL. Role of platelet plasma membrane Ca-ATPase in health and disease. World J Biol Chem 2010; 1: 265-70.
-
(2010)
World J Biol Chem
, vol.1
, pp. 265-270
-
-
Dean, W.L.1
-
46
-
-
0025868650
-
Increased intracellular calcium mobilization in platelets from patients with type 2 (noninsulin-dependent) diabetes mellitus
-
Ishii H, Umeda F, Hashimoto T, Nawata H. Increased intracellular calcium mobilization in platelets from patients with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 332-6.
-
(1991)
Diabetologia
, vol.34
, pp. 332-336
-
-
Ishii, H.1
Umeda, F.2
Hashimoto, T.3
Nawata, H.4
-
47
-
-
0036096133
-
Glycated low density lipoproteins modify platelet properties: A compositional and functional study
-
Ferretti G, Rabini RA, Bacchetti T, et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87: 2180-4.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 2180-2184
-
-
Ferretti, G.1
Rabini, R.A.2
Bacchetti, T.3
-
48
-
-
0033812287
-
Activated platelets in patients with severe hypertriglyceridemia: Effects of triglyceride-lowering therapy
-
de Man FH, Nieuwland R, van der Laarse A, et al. Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy. Atherosclerosis 2000; 152: 407-14.
-
(2000)
Atherosclerosis
, vol.152
, pp. 407-414
-
-
de Man, F.H.1
Nieuwland, R.2
van der Laarse, A.3
-
49
-
-
0026316004
-
Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity
-
Kuhn FE, Mohler ER, Satler LF, et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991; 68: 1425-30.
-
(1991)
Am J Cardiol
, vol.68
, pp. 1425-1430
-
-
Kuhn, F.E.1
Mohler, E.R.2
Satler, L.F.3
-
50
-
-
0032485927
-
Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo
-
Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-701.
-
(1998)
Circulation
, vol.97
, pp. 1695-1701
-
-
Williams, S.B.1
Goldfine, A.B.2
Timimi, F.K.3
-
51
-
-
0031985026
-
Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM
-
Anfossi G, Mularoni EM, Burzacca S, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998; 21: 121-6.
-
(1998)
Diabetes Care
, vol.21
, pp. 121-126
-
-
Anfossi, G.1
Mularoni, E.M.2
Burzacca, S.3
-
52
-
-
0029085504
-
Activation of tissue factorinduced coagulation and endothelial cell dysfunction in noninsulin-dependent diabetic patients with microalbuminuria
-
Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factorinduced coagulation and endothelial cell dysfunction in noninsulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114-20.
-
(1995)
Arterioscler Thromb Vasc Biol
, vol.15
, pp. 1114-1120
-
-
Kario, K.1
Matsuo, T.2
Kobayashi, H.3
-
54
-
-
65349085512
-
Insulin, insulin resistance, and platelet signaling in diabetes
-
Randriamboavonjy V, Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care 2009; 32: 528-30.
-
(2009)
Diabetes Care
, vol.32
, pp. 528-530
-
-
Randriamboavonjy, V.1
Fleming, I.2
-
55
-
-
0033045148
-
Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: Does increased platelet activation contribute to platelet size heterogeneity?
-
Watala C, Boncler M, Pietrucha T, Trojanowski Z. Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity? Platelets 1999; 10: 52-60.
-
(1999)
Platelets
, vol.10
, pp. 52-60
-
-
Watala, C.1
Boncler, M.2
Pietrucha, T.3
Trojanowski, Z.4
-
56
-
-
60849111109
-
Immature platelets in patients with acute coronary syndromes
-
Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009;101:151-6.
-
(2009)
Thromb Haemost
, vol.101
, pp. 151-156
-
-
Grove, E.L.1
Hvas, A.M.2
Kristensen, S.D.3
-
57
-
-
78650952436
-
Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease
-
Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-91.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 185-191
-
-
Grove, E.L.1
Hvas, A.M.2
Mortensen, S.B.3
Larsen, S.B.4
Kristensen, S.D.5
-
58
-
-
79959835019
-
Increased platelet turnover in patients with previous definite stent thrombosis
-
Grove EL, Wurtz M, Hvas AM, Kristensen SD. Increased platelet turnover in patients with previous definite stent thrombosis. J Thromb Haemost 2011; 9: 1418-9.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 1418-1419
-
-
Grove, E.L.1
Wurtz, M.2
Hvas, A.M.3
Kristensen, S.D.4
-
59
-
-
18444377050
-
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets
-
Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 7634-7639
-
-
Rocca, B.1
Secchiero, P.2
Ciabattoni, G.3
-
60
-
-
77953160638
-
A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease
-
Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-53.
-
(2010)
Thromb Haemost
, vol.103
, pp. 1245-1253
-
-
Grove, E.L.1
Hvas, A.M.2
Johnsen, H.L.3
-
61
-
-
0018830990
-
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
-
Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-27.
-
(1980)
Thromb Res
, vol.17
, pp. 317-327
-
-
Patrono, C.1
Ciabattoni, G.2
Pinca, E.3
-
62
-
-
33645745392
-
Dose-and time-dependent antiplatelet effects of aspirin
-
Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose-and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-8.
-
(2006)
Thromb Haemost
, vol.95
, pp. 652-658
-
-
Perneby, C.1
Wallen, N.H.2
Rooney, C.3
Fitzgerald, D.4
Hjemdahl, P.5
-
63
-
-
64649098177
-
Optical platelet aggregation vs. thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration
-
Hedegaard SS, Hvas AM, Grove EL, et al. Optical platelet aggregation vs. thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res 2009; 124: 96-100.
-
(2009)
Thromb Res
, vol.124
, pp. 96-100
-
-
Hedegaard, S.S.1
Hvas, A.M.2
Grove, E.L.3
-
65
-
-
0019988413
-
Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
-
Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
-
(1982)
J Clin Invest
, vol.69
, pp. 1366-1372
-
-
Patrignani, P.1
Filabozzi, P.2
Patrono, C.3
-
66
-
-
0023804098
-
Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
-
ISIS-2 (Second International Study of Infarct Survival) CollaborativeGroup
-
ISIS-2 (Second International Study of Infarct Survival) CollaborativeGroup. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 1988; 12: 3A-13A.
-
(1988)
J Am Coll Cardiol
, vol.12
-
-
-
67
-
-
0037065502
-
Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
-
Antithrombotic Trialists' Collaboration
-
Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
-
(2002)
BMJ
, vol.324
, pp. 71-86
-
-
-
70
-
-
33749187494
-
Quantifying the effect of antiplatelet therapy: A comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry
-
Agarwal S, Coakley M, Reddy K, Riddell A, Mallett S. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105: 676-83.
-
(2006)
Anesthesiology
, vol.105
, pp. 676-683
-
-
Agarwal, S.1
Coakley, M.2
Reddy, K.3
Riddell, A.4
Mallett, S.5
-
71
-
-
75149180515
-
Standards of medical care in diabetes-2010
-
Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 (Suppl 1): S11-S61.
-
(2010)
Diabetes Care
, vol.33
, Issue.SUPPL. 1
-
-
-
72
-
-
0345411332
-
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial
-
Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-72.
-
(2003)
Diabetes Care
, vol.26
, pp. 3264-3272
-
-
Sacco, M.1
Pellegrini, F.2
Roncaglioni, M.C.3
-
73
-
-
15744378579
-
A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women
-
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
-
(2005)
N Engl J Med
, vol.352
, pp. 1293-1304
-
-
Ridker, P.M.1
Cook, N.R.2
Lee, I.M.3
-
74
-
-
65849268320
-
Aspirin in the primary and secondary prevention of vascular disease: Collaborative metaanalysis of individual participant data from randomised trials
-
Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
-
(2009)
Lancet
, vol.373
, pp. 1849-1860
-
-
Baigent, C.1
Blackwell, L.2
Collins, R.3
-
75
-
-
80053638595
-
Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis
-
Madsen EH, Gehr NR, Johannesen NL, Schmidt EB, Kristensen SR. Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets 2011; 22: 537-46.
-
(2011)
Platelets
, vol.22
, pp. 537-546
-
-
Madsen, E.H.1
Gehr, N.R.2
Johannesen, N.L.3
Schmidt, E.B.4
Kristensen, S.R.5
-
76
-
-
79851485625
-
Why an aspirin a day no longer keeps the doctor away
-
Lordkipanidze M. Why an aspirin a day no longer keeps the doctor away. Thromb Haemost 2011; 105: 209-10.
-
(2011)
Thromb Haemost
, vol.105
, pp. 209-210
-
-
Lordkipanidze, M.1
-
77
-
-
0022970057
-
Trial of repeated low-dose aspirin in diabetic angiopathy
-
DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91.
-
(1986)
Blood
, vol.68
, pp. 886-891
-
-
DiMinno, G.1
Silver, M.J.2
Cerbone, A.M.3
Murphy, S.4
-
78
-
-
79959318812
-
Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease
-
Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4: 180-7.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, pp. 180-187
-
-
Capodanno, D.1
Patel, A.2
Dharmashankar, K.3
-
79
-
-
42249091189
-
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel
-
van Werkum JW, Topcu Y, Postma S, et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008; 99: 637-9.
-
(2008)
Thromb Haemost
, vol.99
, pp. 637-639
-
-
van Werkum, J.W.1
Topcu, Y.2
Postma, S.3
-
80
-
-
36849082996
-
The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study
-
DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007; 56: 3014-9.
-
(2007)
Diabetes
, vol.56
, pp. 3014-3019
-
-
DiChiara, J.1
Bliden, K.P.2
Tantry, U.S.3
-
81
-
-
46749087824
-
Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease
-
Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
-
(2008)
Thromb Haemost
, vol.100
, pp. 76-82
-
-
Serebruany, V.1
Pokov, I.2
Kuliczkowski, W.3
Chesebro, J.4
Badimon, J.5
-
82
-
-
34948875324
-
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
-
Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-7.
-
(2007)
J Am Coll Cardiol
, vol.50
, pp. 1541-1547
-
-
Angiolillo, D.J.1
Bernardo, E.2
Sabate, M.3
-
83
-
-
62549109074
-
Low dose aspirin does not maintain a 24-hour biological efficacy in type-2 diabetic patients
-
Sideris G, Guyetand C, Belluci S, et al. Low dose aspirin does not maintain a 24-hour biological efficacy in type-2 diabetic patients. Eur Heart J 2007; 28 Suppl: 267.
-
(2007)
Eur Heart J
, vol.28
, Issue.SUPPL.
, pp. 267
-
-
Sideris, G.1
Guyetand, C.2
Belluci, S.3
-
84
-
-
79958770159
-
Terutroban vs. aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
-
Bousser MG, Amarenco P, Chamorro A, et al. Terutroban vs. aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013-22.
-
(2011)
Lancet
, vol.377
, pp. 2013-2022
-
-
Bousser, M.G.1
Amarenco, P.2
Chamorro, A.3
-
85
-
-
46049090018
-
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 776S-814S.
-
(2008)
Chest
, vol.133
-
-
Becker, R.C.1
Meade, T.W.2
Berger, P.B.3
-
86
-
-
24944565392
-
Is clopidogrel the antiplatelet drug of choice for highrisk patients with stroke/TIA?: Yes
-
Diener HC. Is clopidogrel the antiplatelet drug of choice for highrisk patients with stroke/TIA?: Yes. J Thromb Haemost 2005; 3: 1133-6.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 1133-1136
-
-
Diener, H.C.1
-
87
-
-
51449116270
-
Aspirin and extended-release dipyridamole vs. clopidogrel for recurrent stroke
-
Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole vs. clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
-
(2008)
N Engl J Med
, vol.359
, pp. 1238-1251
-
-
Sacco, R.L.1
Diener, H.C.2
Yusuf, S.3
-
88
-
-
58249135635
-
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
-
Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-17.
-
(2009)
Lancet
, vol.373
, pp. 309-317
-
-
Collet, J.P.1
Hulot, J.S.2
Pena, A.3
-
89
-
-
78650317150
-
Genetic variability in response to clopidogrel therapy: Clinical implications
-
Huber K. Genetic variability in response to clopidogrel therapy: clinical implications. Eur Heart J 2010; 31: 2974-6.
-
(2010)
Eur Heart J
, vol.31
, pp. 2974-2976
-
-
Huber, K.1
-
90
-
-
56849130022
-
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
-
Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-77.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 1968-1977
-
-
Erlinge, D.1
Varenhorst, C.2
Braun, O.O.3
-
91
-
-
61549124132
-
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
-
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
-
(2009)
JAMA
, vol.301
, pp. 937-944
-
-
Ho, P.M.1
Maddox, T.M.2
Wang, L.3
-
93
-
-
0030590746
-
A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE)
-
CAPRIE Steering Committee
-
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
-
(1996)
Lancet
, vol.348
, pp. 1329-1339
-
-
-
94
-
-
0037106972
-
Amplified benefit of clopidogrel vs. aspirin in patients with diabetes mellitus
-
Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel vs. aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-8.
-
(2002)
Am J Cardiol
, vol.90
, pp. 625-628
-
-
Bhatt, D.L.1
Marso, S.P.2
Hirsch, A.T.3
-
95
-
-
0035899289
-
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation
-
Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med 2001; 345: 494-502.
-
(2001)
N Engl J Med
, vol.345
, pp. 494-502
-
-
Yusuf, S.1
Zhao, F.2
Mehta, S.R.3
-
96
-
-
0037145863
-
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
-
Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
-
(2002)
JAMA
, vol.288
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann III, J.T.3
-
97
-
-
20144373281
-
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
-
Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
-
(2005)
N Engl J Med
, vol.352
, pp. 1179-1189
-
-
Sabatine, M.S.1
Cannon, C.P.2
Gibson, C.M.3
-
98
-
-
27644548513
-
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial
-
Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
-
(2005)
Lancet
, vol.366
, pp. 1607-1621
-
-
Chen, Z.M.1
Jiang, L.X.2
Chen, Y.P.3
-
99
-
-
33645861080
-
Clopidogrel and aspirin vs. aspirin alone for the prevention of atherothrombotic events
-
Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin vs. aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
-
(2006)
N Engl J Med
, vol.354
, pp. 1706-1717
-
-
Bhatt, D.L.1
Fox, K.A.2
Hacke, W.3
-
101
-
-
75749102996
-
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans
-
Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-42.
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 126-142
-
-
Farid, N.A.1
Kurihara, A.2
Wrighton, S.A.3
-
102
-
-
46449103184
-
The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2
-
Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008; 36: 1227-32.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 1227-1232
-
-
Williams, E.T.1
Jones, K.O.2
Ponsler, G.D.3
-
103
-
-
36849074168
-
Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
-
Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-74.
-
(2007)
Cardiovasc Drug Rev
, vol.25
, pp. 357-374
-
-
Jakubowski, J.A.1
Winters, K.J.2
Naganuma, H.3
Wallentin, L.4
-
104
-
-
37349111065
-
Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
-
Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-32.
-
(2007)
Circulation
, vol.116
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
-
105
-
-
36348943475
-
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
-
Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-36.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2429-2436
-
-
Brandt, J.T.1
Close, S.L.2
Iturria, S.J.3
-
106
-
-
79952149001
-
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
-
Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011; 32: 838-46.
-
(2011)
Eur Heart J
, vol.32
, pp. 838-846
-
-
Angiolillo, D.J.1
Badimon, J.J.2
Saucedo, J.F.3
-
107
-
-
36148983750
-
Prasugrel vs. clopidogrel in patients with acute coronary syndromes
-
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
-
(2007)
N Engl J Med
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
-
108
-
-
77955690680
-
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial
-
Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16-22.
-
(2010)
Am Heart J
, vol.160
, pp. 16-22
-
-
Chin, C.T.1
Roe, M.T.2
Fox, K.A.3
-
109
-
-
55949103494
-
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38
-
Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-36.
-
(2008)
Circulation
, vol.118
, pp. 1626-1636
-
-
Wiviott, S.D.1
Braunwald, E.2
Angiolillo, D.J.3
-
110
-
-
34548841427
-
From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
-
Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007; 17: 6013-8.
-
(2007)
Bioorg Med Chem Lett
, vol.17
, pp. 6013-6018
-
-
Springthorpe, B.1
Bailey, A.2
Barton, P.3
-
111
-
-
77950508416
-
Response to ticagrelor in clopidogrel non-responders and responders and effect of switching therapies: The RESPOND study
-
Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel non-responders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-99.
-
(2010)
Circulation
, vol.121
, pp. 1188-1199
-
-
Gurbel, P.A.1
Bliden, K.P.2
Butler, K.3
-
112
-
-
79960189314
-
The effect of ticagrelor vs. clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies
-
Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor vs. clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011; 162: 160-5.
-
(2011)
Am Heart J
, vol.162
, pp. 160-165
-
-
Bliden, K.P.1
Tantry, U.S.2
Storey, R.F.3
-
113
-
-
79951785678
-
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor vs. clopidogrel: The ONSET/OFFSET and RESPOND genotype studies
-
Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor vs. clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010; 3: 556-66.
-
(2010)
Circ Cardiovasc Genet
, vol.3
, pp. 556-566
-
-
Tantry, U.S.1
Bliden, K.P.2
Wei, C.3
-
114
-
-
70149101223
-
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes
-
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
115
-
-
78650368771
-
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
-
James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31: 3006-16.
-
(2010)
Eur Heart J
, vol.31
, pp. 3006-3016
-
-
James, S.1
Angiolillo, D.J.2
Cornel, J.H.3
-
116
-
-
46049108934
-
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233S.
-
(2008)
Chest
, vol.133
-
-
Patrono, C.1
Baigent, C.2
Hirsh, J.3
Roth, G.4
-
117
-
-
0037335810
-
Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo/ex vivo studies
-
Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34: 764-9.
-
(2003)
Stroke
, vol.34
, pp. 764-769
-
-
Aktas, B.1
Utz, A.2
Hoenig-Liedl, P.3
Walter, U.4
Geiger, J.5
-
118
-
-
0030297319
-
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
-
Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
-
(1996)
J Neurol Sci
, vol.143
, pp. 1-13
-
-
Diener, H.C.1
Cunha, L.2
Forbes, C.3
-
119
-
-
11144246091
-
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials
-
Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36: 162-8.
-
(2005)
Stroke
, vol.36
, pp. 162-168
-
-
Leonardi-Bee, J.1
Bath, P.M.2
Bousser, M.G.3
-
120
-
-
33646596912
-
Aspirin plus dipyridamole vs. aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial
-
Halkes PH, van GJ, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole vs. aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
-
(2006)
Lancet
, vol.367
, pp. 1665-1673
-
-
Halkes, P.H.1
Van, G.J.2
Kappelle, L.J.3
Koudstaal, P.J.4
Algra, A.5
-
122
-
-
44349138210
-
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
-
Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008; 155: 1081-9.
-
(2008)
Am Heart J
, vol.155
, pp. 1081-1089
-
-
Biondi-Zoccai, G.G.1
Lotrionte, M.2
Anselmino, M.3
-
123
-
-
77956884231
-
Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial
-
Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-68.
-
(2010)
Lancet Neurol
, vol.9
, pp. 959-968
-
-
Shinohara, Y.1
Katayama, Y.2
Uchiyama, S.3
-
124
-
-
39849087752
-
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial
-
Ahn Y, Jeong MH, Jeong JW, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008; 72: 35-9.
-
(2008)
Circ J
, vol.72
, pp. 35-39
-
-
Ahn, Y.1
Jeong, M.H.2
Jeong, J.W.3
-
125
-
-
77955428270
-
Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: A meta-analysis
-
Jennings DL, Kalus JS. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol 2010; 50: 415-21.
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 415-421
-
-
Jennings, D.L.1
Kalus, J.S.2
-
126
-
-
73149120546
-
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and-LONG Trials)
-
Lee SW, Chun KJ, Park SW, et al. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and-LONG Trials). Am J Cardiol 2010; 105: 168-73.
-
(2010)
Am J Cardiol
, vol.105
, pp. 168-173
-
-
Lee, S.W.1
Chun, K.J.2
Park, S.W.3
-
127
-
-
52449085759
-
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study
-
Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008; 29: 2202-11.
-
(2008)
Eur Heart J
, vol.29
, pp. 2202-2211
-
-
Angiolillo, D.J.1
Capranzano, P.2
Goto, S.3
-
128
-
-
28344436780
-
Protease-activated receptors in hemostasis, thrombosis and vascular biology
-
Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-14.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 1800-1814
-
-
Coughlin, S.R.1
-
129
-
-
58149143160
-
Basic and translational research on proteinase-activated receptors: Antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease
-
Chintala M, Shimizu K, Ogawa M, et al. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 2008; 108: 433-8.
-
(2008)
J Pharmacol Sci
, vol.108
, pp. 433-438
-
-
Chintala, M.1
Shimizu, K.2
Ogawa, M.3
-
130
-
-
61849180442
-
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study
-
Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-28.
-
(2009)
Lancet
, vol.373
, pp. 919-928
-
-
Becker, R.C.1
Moliterno, D.J.2
Jennings, L.K.3
-
131
-
-
78149355554
-
Doubleblind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
-
Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL. Doubleblind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010; 31: 2601-13.
-
(2010)
Eur Heart J
, vol.31
, pp. 2601-2613
-
-
Goto, S.1
Ogawa, H.2
Takeuchi, M.3
Flather, M.D.4
Bhatt, D.L.5
-
132
-
-
85027951718
-
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: The lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial
-
Wiviott SD, Flather MD, O'Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 2011; 123: 1854-63.
-
(2011)
Circulation
, vol.123
, pp. 1854-1863
-
-
Wiviott, S.D.1
Flather, M.D.2
O'Donoghue, M.L.3
-
133
-
-
85027946204
-
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: The lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial
-
O'Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 2011; 123: 1843-53.
-
(2011)
Circulation
, vol.123
, pp. 1843-1853
-
-
O'Donoghue, M.L.1
Bhatt, D.L.2
Wiviott, S.D.3
-
136
-
-
79955618078
-
Inhibitors of the platelet thrombin receptor: Will they live up to their promises?
-
Van de Werf F. Inhibitors of the platelet thrombin receptor: will they live up to their promises? Circulation 2011; 123: 1833-5.
-
(2011)
Circulation
, vol.123
, pp. 1833-1835
-
-
van de Werf, F.1
-
137
-
-
33846083971
-
Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association
-
Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-26.
-
(2007)
Circulation
, vol.115
, pp. 114-126
-
-
Buse, J.B.1
Ginsberg, H.N.2
Bakris, G.L.3
-
138
-
-
74449086639
-
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
-
Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 2010; 87: 211-8.
-
(2010)
Diabetes Res Clin Pract
, vol.87
, pp. 211-218
-
-
Zhang, C.1
Sun, A.2
Zhang, P.3
-
139
-
-
77950511412
-
Executive summary: Standards of medical care in diabetes-2010
-
Executive summary: Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 Suppl 1: S4-10.
-
(2010)
Diabetes Care
, vol.33
, Issue.SUPPL. 1
-
-
-
140
-
-
79958001356
-
The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary
-
Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 2011; 27: 208-21.
-
(2011)
Can J Cardiol
, vol.27
, pp. 208-221
-
-
Bell, A.D.1
Roussin, A.2
Cartier, R.3
-
141
-
-
79251601596
-
Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association
-
Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517-84.
-
(2011)
Stroke
, vol.42
, pp. 517-584
-
-
Goldstein, L.B.1
Bushnell, C.D.2
Adams, R.J.3
-
142
-
-
34548329882
-
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)
-
Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): E1-40.
-
(2007)
Eur J Cardiovasc Prev Rehabil
, vol.14
, Issue.SUPPL. 2
-
-
Graham, I.1
Atar, D.2
Borch-Johnsen, K.3
-
144
-
-
35348816110
-
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
-
De BG, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8: 21.
-
(2007)
Trials
, vol.8
, pp. 21
-
-
De, B.G.1
Sacco, M.2
Evangelista, V.3
-
145
-
-
77958035098
-
-
British Heart Foundation, Bayer, University of Oxford, and Solvay Pharmaceuticals, (accessed 21-7-2011)
-
British Heart Foundation, Bayer, University of Oxford, and Solvay Pharmaceuticals: ASCEND: A Study of Cardiovascular Events iN Diabetes http://www.clinicaltrials.gov/ct2/show/NCT00135226term=A+Stu dy+of+Cardiovascular+Events+in+Diabetes&rank=1 (accessed 21-7-2011).
-
ASCEND: A Study of Cardiovascular Events iN Diabetes
-
-
-
146
-
-
77749258073
-
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin vs. no aspirin in patients with multiple risk factors for vascular events
-
Teramoto T, Shimada K, Uchiyama S, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin vs. no aspirin in patients with multiple risk factors for vascular events. Am Heart J 2010; 159: 361-9.
-
(2010)
Am Heart J
, vol.159
, pp. 361-369
-
-
Teramoto, T.1
Shimada, K.2
Uchiyama, S.3
|